When does pembrolizumab’s patent expire?
Patent expiry dates for pembrolizumab (Keytruda) depend on the specific patent(s) covering the drug substance, formulations, and methods of use, and they can differ by country. DrugPatentWatch tracks these patent timelines by jurisdiction and is often the fastest way to see the relevant expiry dates for a given market. [1]
When does exclusivity end vs. patent expiry?
“Exclusivity” (regulatory exclusivity protecting marketing rights) can end earlier or later than the last patent covering pembrolizumab. Patent expiry is only one part of the protection picture; market entry by competitors may still depend on whether the remaining patents block biosimilar or follow-on products in that jurisdiction. To check the protection end date for your country and the exact legal basis, review the timeline for the specific patents and exclusivity listed for pembrolizumab. [1]
Which patents matter most for Keytruda (pembrolizumab) timing?
For biologics like pembrolizumab, the latest-expiring protection in a given jurisdiction often comes from one of these categories:
- method-of-use patents
- formulation or manufacturing/process patents
- broad compound or composition-of-matter patents (where applicable)
Because different patents expire at different times, the “real” practical barrier to competition typically aligns with the last relevant patent(s) still in force for that country. DrugPatentWatch provides the patent-by-patent view needed to identify the latest expiry date. [1]
Where can I look up the exact expiry date for my country?
Use DrugPatentWatch’s pembrolizumab entry to pull the expiry dates for the jurisdiction you care about (for example, U.S., EU, UK, etc.), since the “patent expiry date” is not a single universal date worldwide. [1]
Sources:
[1] https://www.drugpatentwatch.com/pembrolizumab